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ABSTRACT
Majority of giant-cell tumours of bone are benign with locally malignant potential. In some patients, the clinical 
course may be more aggressive, and treatment is not always effective. An individual therapeutic approach may 
then be of benefit, including bone remodelling agents, chemotherapy, radiotherapy, and possibly immunotherapy, 
in a future perspective.
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Introduction
Giant-cell tumour of bone is a neoplasm of some 
locally malignant potential. In some patients, the 
clinical course may be more aggressive, which neces-
sitates a more intensive management, that might not 
be effective. An individual therapeutic approach, with 
multimodal treatment protocols, may then be of benefit
The authors present herein a case report of a pa-
tient with lung metastases of giant-cell tumour of bone, 
in whom sequential application of systemic and local 
therapy resulted in a significant clinical benefit and 
disease control.
Case report
A 26-year-old male patient presented in September 
2009 to the surgical outpatient clinic of the Lower Sile-
sian Oncology Centre (DCO, Dolnośląskie Centrum 
Onkologii) in Wrocław because of sensory symptoms 
and the presence of a tumour in the left upper limb. 
The patient reported numbness and paraesthesia in the 
fingers of his left hand supplied by the left ulnar nerve, 
which had begun in May that year. He was referred to 
an orthopaedic surgeon in August.
On admission, physical examination revealed a tu-
mour in the lower part of the left forearm, painful to 
palpation. X-ray picture showed a five-centimetre-long 
osteolytic dilatation of the left distal ulnar bone, with 
thinned and locally disrupted cortex, periosteal thick-
ening, and soft tissue engagement.
There were no signs of disease dissemination on 
radiological staging (T1N0M0).
Open biopsy of the ulnar tumour was performed on 
October 30th, 2009. Histopathological investigation iden-
tified giant-cell tumour of bone (GCT). The patient was 
qualified for elective surgery, and the tumour was resected 
with distal 1/3 of the ulnar bone on December 2nd, 2009.
Postoperative histopathological report confirmed 
the diagnosis of GCT with low proliferative activity. 
Focal necrosis and haemorrhages were found in the 
sample, which could suggest some malignant potential 
and risk of recurrence. Adjuvant radiotherapy (RT) was 
first considered but not undertaken given the radical 
excision, and active follow-up was chosen instead.
In March 2010, the patient observed a centime-
tre-long thickening of the distal part of postoperative 
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scar. Radiological investigation showed no pathological 
lesions, and further follow-up was scheduled.
Control X-ray performed in February 2011 revealed 
a local lesion of uncertain character, and computed axial 
tomography (CAT) was decided. CAT scans showed 
findings consistent with local postoperative lesions of 
3.3 × 3 × 6 cm, with no contrast enhancement. Magnetic 
resonance imaging (MRI) was decided to perform but 
the patient did not attend. The investigation was per-
formed in January 2012, and a 5-cm tumour was found 
in the previously operated area.
Chest X-ray disclosed multiple bilateral pulmonary 
metastases of up to 2.6 cm, and upper left limb MRI 
showed a local tumour recurrence of 7.3 × 6.5 × 13 cm. 
The patient was referred for consultation to the Maria 
Skłodowska-Curie Institute of Oncology in Warsaw, 
where tumour recurrence was confirmed on histopatho-
logical reexamination. The patient was then qualified 
for the clinical study involving denosumab.
Treatment with denosumab was carried on from 
May 2012 until February 2013, when progression of lung 
lesions was observed radiologically. As sarcomatous 
transformation was suspected, the patient discontinued 
treatment within the study, and chemotherapy (CT) was 
initiated (AP3 protocol: doxorubicin 20 mg/m2, cisplatin 
30 mg/m2 on days 1–3, repeated every 21 days).
Chemotherapy was continued in Wrocław, and the 
patient received three courses of treatment between 
April 10th and May 25th, 2013. Under treatment, pro-
gression of both the limb tumour and the lung lesions 
(increasing number and size of lesions) was observed. 
The tumour in the forearm was then 11 × 8 × 7 cm 
in size, the lesion was soft to palpation, fixed, causing 
progressive spasticity of left hand fingers and pain. In 
June 2013, the chemotherapy protocol was changed 
to ifosfamide (IFO 5,000 mg/m2 every 21 days) com-
bined with palliative RT due to progression of lesions 
and symptoms.
Between June and July 2013, the patient received 
30 Gy in 10 fractions to the tumour site, which resulted 
in a marked symptom decrease. As multiple bilateral 
lung lesions persisted and the patient’s performance 
status was good, palliative chemotherapy using IFO 
was continued.
A total of 32 chemotherapy cycles were adminis-
tered between June 2013 and August 2015 and treat-
ment was well tolerated with the exception of single 
transient ischaemic attack (TIA), that caused a short 
pause in therapy. Treatment resulted in an improved 
local status and stabilisation of lung lesions. However, 
from February 2015 both the lesion in the forearm and 
lung metastases began to progress again. Chemotherapy 
was stopped, and RT was reintroduced, with adminis-
tration of 30 Gy in 10 fractions to the limb recurrence 
in November 2015.
At that time, chest X-ray revealed slowing down of 
the disease progression (with lung lesions up to 46 mm 
in diameter). Consecutive CAT scans, taken between 
November 2015 and October 2016, pointed to tumour 
stabilisation, with gradual decrease of the dimensions 
of lung lesions.
Episodes of transient left-sided hemiparesis were 
observed in July and September 2016. Head MRI scans 
excluded central nervous system (CNS) dissemination. 
The patient was from then on followed by a neurologist 
and controlled in a chemotherapy outpatient clinic.
A chest X-ray from October 3rd, 2016 demonstrated 
further shrinking of metastatic lesions (the greatest of 
37 mm in diameter). The disease had been stable for 
1.5 years at that time, and the neurologist suggested 
portacath removal, which was performed in December 
2016. Control chest X-ray (March 7th, 2017) showed 
stable lung lesions as compared to the previous inves-
tigation. 
The patient remains under clinical supervision, has 
a good performance status, with no signs of local or 
distant lesion progression.
Summary and discussion
Giant-cell tumour of bone is rare neoplasm, with 
slight predominance in women, occurring mainly in 
limbs and more rarely in axial skeleton and pelvis. Euro-
pean and US statistics show that GCT represents 5% of 
all bone tumours and 21% of benign skeletal neoplasms.
Data from the National Cancer Institute (NCI) 
show that the prevalence of GCT in the USA is 1.6 per 
10,000 inhabitants per year, with slightly increased num-
ber of cases in patients between 20 and 44 years of age 
[1]. The authors could not retrieve prevalence figures 
for the Polish population.
Giant-cell tumours most often have benign character 
and confer good prognosis but may progress locally in 
up to 65% patients and cause local bone destruction [2].
The tumours may, however, transform or produce 
distant metastases. Less than 5% of recurrent GCTs 
harbour lung metastases, that occur on average 3‒5 years 
from diagnosis. Pulmonary lesions tend to grow slowly 
— sometimes are referred to as “tumour deposits” and 
may regress spontaneously under follow-up. In a small 
proportion of cases, sarcomatous cells may be identified 
in tumour tissue, which suggests a higher malignancy 
potential. Such tumours may demonstrate an aggressive 
growth and lead to patient death [3].
Localised disease is treated by radical surgical exci-
sion, preceded by open biopsy. Radiotherapy may be 
considered in cases of uncertain malignant potential, 
non-radical excision when wider resection is not pos-
sible, in non-operable locations, and when surgical 
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treatment cannot be carried out, e.g. due to concomitant 
diseases [4, 5].
Inoperable GCT may be treated with denosumab, 
humanised monoclonal IgG2 antibody, binding to the 
receptor activator of nuclear factor kappa-B ligand 
(RANKL), thus preventing its interaction with RANK.
Stromal cells of GCT express RANKL and thereby 
interact with osteoclast-like giant cells, which are in turn 
positive for RANK. This binding impairs the balance 
between bone formation and tumour-induced resorp-
tion and destruction.
The beneficial effect of denosumab in patients 
with GCT is related to the reduction of the number 
or elimination of osteoclast-like giant cells, caused by 
RANKL binding. This results in osteolysis inhibition, 
and the proliferating tumour stroma is replaced by 
proliferation-quiescent compact, differentiated bone 
tissue. Disease progression is stopped, performance 
status is improved, and pain reduction is observed in 
up to 80% of patients. The agent is administered for 
GCT therapy subcutaneously, 120 mg every four weeks, 
with additional doses on day 8 and day 15 of the first 
treatment cycle [6–8].
Optimal treatment of distant metastases includes 
surgical resection, which may be considered if the pri-
mary lesion is well controlled.
Chemotherapy plays a marginal role in the treatment 
of GCTs, and is applied in cases of suspected local sar-
comatous transformation. Single reports of attempted 
interferon alpha treatment in disseminated disease can 
be found in literature [9, 10].
The presented patient was not suited for resection 
of secondary lesions, which were multiple and located 
in both lungs. Besides, progression of the primary limb 
tumour was observed.
Denosumab modulates bone metabolism, and in 
the presented patient led to control of disease that had 
been disseminated for nine months. Doxorubicin-based 
chemotherapy is most commonly used in the treatment 
of sarcomas but could not inhibit disease progression 
in the presented patient. Ifosfamide was well toler-
ated and efficient for more than 13 months. After 
completion of chemotherapy and repeated local radio-
therapy, an eighteen-month’ progression-free survival 
was achieved.
Several case reports of spontaneous regression of 
GCT metastases can be found in literature. This would 
be highly unlikely in the presented patient, given the 
quite aggressive initial course and progressive disease 
character. Local therapy seemed most efficient in this 
case. Regression of the primary lesion was obtained after 
two courses of RT with a total dose of 60 Gy, which could 
also have an impact on distant metastases.
This might be explained by the so-called “abscopal 
effect” (ab — away from, scopus — target), a term used 
to describe regression of secondary lesions in cases of 
disseminated disease after local RT applied only to the 
primary tumour focus.
This phenomenon was described in malignan-
cies strongly affecting the immune system, including 
lymphoma, melanoma, and renal tumours [11]. Some 
authors explain this effect by the impact of radiotherapy 
upon the tumoural microenvironment, where infiltration 
by activated T-cells is stimulated. These lymphocytes 
in turn stimulate immune response focused on tumour 
cells, resulting in their destruction. 
This hypothesis gave the grounds to attempt to 
combine radiotherapy and immunotherapy, particu-
larly using CTLA4 and PD1 inhibitors. The strategy is 
undertaken currently in various clinical trials and might 
become a valuable therapeutic option in tumours poorly 
responding to conventional chemotherapy [12].
The study was not financed from external sources.
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